Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Dalton

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
British Journal of Haematology|March 28, 2012
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myelomaTaiga Nishihori, Todd J Alekshun, Kenneth Shain, et al.
Blood|September 29, 2012
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasoneDavid I Lichter, Hadi Danaee, Michael D Pickard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myelomaPaul G Richardson, Edie Weller, Sundar Jagannath, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 9, 2021
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center ExperienceAlexander Ambinder, Matthew Smith, Hua-Ling Tsai, et al.
Immunity|April 18, 2024
Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophagesJay K Mandula, Rosa A Sierra-Mondragon, Rachel V Jimenez, et al.
Cancer Research|June 3, 2026
Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple MyelomaRafael R Canevarolo, Praneeth Reddy Sudalagunta, Mark B Meads, et al.
Cancer Research|October 30, 2024
The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple MyelomaPraneeth Reddy Sudalagunta, Rafael R Canevarolo, Mark B Meads, et al.
Research Square|June 12, 2026
The Oncology Research Information Exchange Network (ORIEN) - Building a real-world collaborative, patient-driven infrastructure for discovery research and precision oncologyMichelle Churchman, Xin Lu, David McKean, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|June 24, 2019
Evaluating the value of intrapartum fetal scalp blood sampling to predict adverse neonatal outcomes: A UK multicentre observational studyBassel H Al Wattar, Aarti Lakhiani, Adalina Sacco, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
British Journal of Haematology|March 28, 2012
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myelomaTaiga Nishihori, Todd J Alekshun, Kenneth Shain, et al.
Blood|September 29, 2012
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasoneDavid I Lichter, Hadi Danaee, Michael D Pickard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myelomaPaul G Richardson, Edie Weller, Sundar Jagannath, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 9, 2021
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center ExperienceAlexander Ambinder, Matthew Smith, Hua-Ling Tsai, et al.
Immunity|April 18, 2024
Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophagesJay K Mandula, Rosa A Sierra-Mondragon, Rachel V Jimenez, et al.
Cancer Research|June 3, 2026
Integrated Genomic and Epigenomic Analysis Reveals Epigenetic Plasticity in Disease Progression and Multidrug Resistance in Multiple MyelomaRafael R Canevarolo, Praneeth Reddy Sudalagunta, Mark B Meads, et al.
Cancer Research|October 30, 2024
The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple MyelomaPraneeth Reddy Sudalagunta, Rafael R Canevarolo, Mark B Meads, et al.
Research Square|June 12, 2026
The Oncology Research Information Exchange Network (ORIEN) - Building a real-world collaborative, patient-driven infrastructure for discovery research and precision oncologyMichelle Churchman, Xin Lu, David McKean, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|June 24, 2019
Evaluating the value of intrapartum fetal scalp blood sampling to predict adverse neonatal outcomes: A UK multicentre observational studyBassel H Al Wattar, Aarti Lakhiani, Adalina Sacco, et al.
Pageof 3